Olmetec Dosage/Direction for Use

Adults: Recommended Starting Dose: 20 mg once daily; however, dosage must be individualized. If additional blood pressure reduction is required, olmesartan medoxomil dose may be increased to a maximum of 40 mg daily or hydrochlorothiazide therapy may be added.
For patients with possible depletion of intravascular volume, particularly those with impaired renal function, Olmetec should be administered under close medical supervision and consideration should be given to a lower starting dose.
The antihypertensive effect of olmesartan medoxomil is substantially present within 2 weeks of initiating therapy and is maximal by about 8 weeks after initiating therapy. This should be borne in mind when considering change in the dose regimen for any patient.
In order to assist compliance, it is recommended that Olmetec tablets be taken at about the same time each day, with or without food eg, at breakfast time.
Elderly: No initial dosage recommendation is recommended for elderly patients. The daily dose in elderly patients should not exceed 20 mg/day.
Renal Impairment: The maximum dose in patients with mild to moderate renal impairment (creatinine clearance of 20-60 mL/min) is 20 mg once daily, owing to limited experience of higher dosages in this patient group. The use of olmesartan medoxomil in patients with severe renal impairment (creatinine clearance <20 mL/min) and patients requiring dialysis is not recommended (see Pharmacokinetics under Actions).
Hepatic Impairment: The use of olmesartan medoxomil is not recommended in patients with hepatic impairment, since there is only limited experience in this patient group.
Children and Adolescents: The safety and efficacy of olmesartan medoxomil have not been established in children and adolescents up to 18 years.